ARCHIVES

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

This article is from The Cancer Letter archive.

Vol. 15 No. 11 | March 10, 1989

Download PDF Visit The Full Archive

Related Articles

NCI Director May Alert Cancer Panel to Freeze On GS-13 Promotion

November 4, 1994

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

October 22, 2004

Rauscher Tells Flood Subcommittee How He Would Spend An Extra $50 Million-On Centers, Grants

April 12, 1974

Cancer Letter Editor Wine Reporting Awards

June 11, 1999

Community Cancer Center Defined

September 27, 1974

Dose Adjustments Of Other Drugs Questioned; Underdosing Or Overdosing?

October 15, 2010